OncoSec Medical Incorporated (ONCS) Receives Consensus Rating of “Buy” from Analysts
OncoSec Medical Incorporated (NASDAQ:ONCS) has been assigned a consensus rating of “Buy” from the six research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $5.33.
A number of equities analysts recently issued reports on the stock. Maxim Group set a $5.00 price objective on shares of OncoSec Medical and gave the stock a “buy” rating in a research report on Saturday, June 3rd. ValuEngine upgraded shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, July 14th. HC Wainwright set a $6.00 price objective on shares of OncoSec Medical and gave the stock a “buy” rating in a research report on Monday, June 12th. Noble Financial reiterated a “buy” rating on shares of OncoSec Medical in a research report on Wednesday, June 14th. Finally, Dawson James reiterated a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Thursday, July 6th.
Shares of OncoSec Medical (NASDAQ:ONCS) opened at 0.92 on Friday. The company has a 50 day moving average of $1.05 and a 200-day moving average of $1.16. The firm’s market cap is $19.47 million. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08.
OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Thursday, June 1st. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.06. On average, analysts expect that OncoSec Medical will post ($1.02) EPS for the current year.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.